Royal London Asset Management Ltd. Increases Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Royal London Asset Management Ltd. grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,675 shares of the biopharmaceutical company’s stock after purchasing an additional 1,152 shares during the quarter. Royal London Asset Management Ltd.’s holdings in Regeneron Pharmaceuticals were worth $45,913,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of REGN. CWM LLC boosted its stake in Regeneron Pharmaceuticals by 2.2% during the second quarter. CWM LLC now owns 2,247 shares of the biopharmaceutical company’s stock worth $2,361,000 after buying an additional 49 shares during the last quarter. Czech National Bank grew its holdings in shares of Regeneron Pharmaceuticals by 8.7% in the second quarter. Czech National Bank now owns 20,212 shares of the biopharmaceutical company’s stock valued at $21,243,000 after purchasing an additional 1,624 shares during the period. Gibson Capital LLC acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth about $284,000. Transform Wealth LLC raised its stake in Regeneron Pharmaceuticals by 2.9% during the second quarter. Transform Wealth LLC now owns 9,052 shares of the biopharmaceutical company’s stock worth $9,514,000 after purchasing an additional 258 shares during the period. Finally, Sequoia Financial Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 5.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,522 shares of the biopharmaceutical company’s stock valued at $1,600,000 after purchasing an additional 73 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on REGN. JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Evercore ISI decreased their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Leerink Partnrs downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,107.29.

Regeneron Pharmaceuticals Stock Up 1.8 %

REGN stock opened at $767.90 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $735.95 and a fifty-two week high of $1,211.20. The company’s 50 day moving average price is $882.14 and its 200 day moving average price is $1,013.01. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm has a market capitalization of $84.38 billion, a price-to-earnings ratio of 19.00, a PEG ratio of 2.89 and a beta of 0.08.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.